Martin A Cheever - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Martin A Cheever

Showing results (31-40 of 35) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 35 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2019

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II StudyMichael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.

The New England Journal of Medicine|April 20, 2016

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaPaul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.

Science Translational Medicine|March 16, 2022

Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.

Nature Cancer|February 5, 2022

Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.

Pageof 4

Search research articles

Showing results (31-40 of 35) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 35 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2019

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II StudyMichael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.

The New England Journal of Medicine|April 20, 2016

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaPaul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.

Science Translational Medicine|March 16, 2022

Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.

Nature Cancer|February 5, 2022

Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.

Pageof 4